Form 4: Akero Therapeutics CEO Andrew Cheng Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' CEO, Andrew Cheng, executed multiple sales of common stock on February 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 10, 2025, Andrew Cheng, the President and CEO of Akero Therapeutics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan previously adopted on August 16, 2024.
• A total of 29,999 shares were sold in multiple transactions at varying weighted-average prices.
• The prices ranged from $51.340 to $55.81 per share.
• Following these transactions, Andrew Cheng still beneficially owns 686,062 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. The stock sales were pre-planned and do not necessarily indicate a negative outlook on the company's future.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to diversify their holdings and avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the transactions should mitigate any significant concerns.

Key Dates

Keywords

Akero Therapeutics, Andrew Cheng, stock sale, Form 4, Rule 10b5-1, insider trading, AKRO